Catalyst Wire Dossier Catalyst Wire Dossier

Biomarker-guided allogeneic CAR-NK cell therapy (single-target or dual-target)

CAR-NK cell therapy · Essen Biotech
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Biomarker-guided allogeneic CAR-NK cell therapy (single-target or dual-target), covering 2026-02-18 to 2026-02-18. Get the full timeline:

Most recent: Clinical Trial Update: Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors [Phase 1, Phase 2]

See pricing